Oral Infigratinib Therapy in Children with Achondroplasia | NEJM Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1–3 selective t...

Super cool story of innovation and persistence in #NEJM. You might remember #infigratinib AKA #BGJ398, which recently lost FDA approval for FGFR2+ #cholangiocarcinoma. Low doses of #infigratinib are promising in a rare genetic skeletal condition #achondroplasia #medsky www.nejm.org/doi/full/10....